Joshua Karam

1 month ago | jnm.snmjournals.org | Julie Constanzo |Timothée David |Aliasghar Parach |Joshua Karam

radioimmunotherapytargeted radionuclide therapy225Acmicroenvironmentbystander immunityT-cell adaptive immunityTumor absorbed dose and tumor volume are among the main parameters involved in the assessment of external beam radiation therapy (EBRT) efficacy (1). In contrast, although absorbed dose or volume changes are considered in radiopharmaceutical therapy (RPT), they are not considered at the therapy planning stage (2).